Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 14, 2025 READ MORE
AACR Conference on Pediatric Cancer: Investigating the cyclin A/B RxL inhibitor CID-078 in pediatric cancers with RB1 loss and high E2F1 October 1, 2025 READ MORE
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer September 25, 2025 READ MORE
Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies September 9, 2025 READ MORE
Nature: Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors August 20, 2025 READ MORE
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition August 20, 2025 READ MORE
Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer June 16, 2025 READ MORE
A Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class Cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle June 2, 2025 READ MORE
